Results 211 to 220 of about 152,178 (350)

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

New England Journal of Medicine, 2017
G. von Minckwitz, M. Procter, E. de Azambuja, D. Zardavas, M. Benyunes, G. Viale, T. Suter, A. Arahmani, N. Rouchet, E. Clark, A. Knott, I. Láng, C. Lévy, D. Yardley, J. Bines, R. Gelber, M. Piccart, J. Baselga   +17 more
semanticscholar   +1 more source

Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment

International Journal of Cancer, Volume 158, Issue 3, Page 633-641, 1 February 2026.
What's new? Although human epidermal growth factor 2‐positive (HER2+) breast cancer is an aggressive malignancy, significant survival benefits are possible with targeted anti‐HER2 therapies. Whether these therapies are used as recommended, however, is unknown. Here, the authors investigated data from population‐based registries in Norway to assess anti‐
Kathrine F. Vandraas, Sarah Hjorth, Cassia B. Trewin‐Nybråten, Giske Ursin, Edoardo Botteri, Bettina Kulle Andreassen, Kristin V. Reinertsen, Egil S. Blix, Bjørn Naume, Nathalie C. Støer   +9 more
wiley   +1 more source

Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer. [PDF]

Breast Cancer Res Treat
Alonso-Romero JL, Martínez-García J, Carrillo-Vicente R, Aramburo AF, Díez AF, Henarejos PS, de la Morena Barrio P, Boix AP, Jiménez MD, Siles JP, Maestre JAP, de Las Heras-Rubio A, Carreño PR.   +12 more
europepmc   +1 more source

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models [PDF]

, 2009
Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann   +5 more
openalex   +1 more source

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

New England Journal of Medicine, 2015
S. Swain, J. Baselga, Sung-Bae Kim, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. Ferrero, A. Schneeweiss, S. Heeson, E. Clark, G. Ross, M. Benyunes, J. Cortés   +13 more
semanticscholar   +1 more source

Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen, Binghua Li, Shengjia Wang, Yongzhong Yao, Zhao Huang, Decai Yu   +5 more
wiley   +1 more source

²²⁵Ac-NOTA-trastuzumab human dosimetry using inter-radionuclide and biological half-life based allometric extrapolation method. [PDF]

EJNMMI Res
Almaslamani M, Kim K, Kim KI, Lim I, Kim HA, Woo SK.   +5 more
europepmc   +1 more source

Supplementary Table 2 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial [PDF]

Monika Graeser, Oleg Gluz, Peter Schmid, Katarzyna Jóźwiak, Christine zu Eulenburg, Friedrich Feuerhake, Valery Volk, Daniel Ulbrich-Gebauer, Claudia Biehl, Mattea Reinisch, Kerstin Lüdtke-Heckenkamp, Andreas Hartkopf, Felix Hilpert, Michael Braun, Jens Uwe Blohmer, Matthias Christgen, Hans Heinrich Kreipe, Ulrike Nitz, Enrico Pelz, Nadia Harbeck, Sherko Kuemmel   +20 more
openalex   +1 more source

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population [PDF]

, 2012
Hasan Körkaya, Gwang-il Kim, April Davis, Fayaz Malik, N. Lynn Henry, Suthinee Ithimakin, Ahmed A. Quraishi, Nader Tawakkol, Rosemarie C. D'Angelo, Amanda K. Paulson, Susan Chung, Tahra Luther, Hayley J. Paholak, Suling Liu, Khaled A. Hassan, Qin Zen, Shawn G. Clouthier, Max S. Wicha   +17 more
openalex   +1 more source

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji   +4 more
wiley   +1 more source